133 related articles for article (PubMed ID: 2139602)
41. Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
Zehnder C; Blumberg A
Clin Nephrol; 1989 Feb; 31(2):55-9. PubMed ID: 2920469
[TBL] [Abstract][Full Text] [Related]
42. The adverse effects of recombinant human erythropoietin therapy.
Wong KC; Li PK; Lui SF; Nicholls MG; Lai KN
Adverse Drug React Acute Poisoning Rev; 1990; 9(4):183-206. PubMed ID: 2088088
[No Abstract] [Full Text] [Related]
43. Analysis of the factors in the cases resistant to recombinant human erythropoietin treatment.
Suzuki M
Contrib Nephrol; 1990; 82():65-71. PubMed ID: 2093529
[No Abstract] [Full Text] [Related]
44. [Indication and administration method in erythropoietin treatment].
Koide K; Inumaru T; Arai T; Momose T; Takeda F; Matsuzaki K; Sano M
Nihon Rinsho; 1991 Dec; 49 Suppl():670-8. PubMed ID: 1808334
[No Abstract] [Full Text] [Related]
45. [Erythropoietin--complications, side effects].
Koide K; Arai T
Nihon Rinsho; 1991 Dec; 49 Suppl():679-87. PubMed ID: 1808335
[No Abstract] [Full Text] [Related]
46. Full results on risks of epoetin emerge 14 years after major dialysis study.
Epstein K
BMJ; 2012 May; 344():e3535. PubMed ID: 22619221
[No Abstract] [Full Text] [Related]
47. Are high flux dialysis and erythropoietin treatment in a collision course?
Acchiardo SR; Quinn BP; Burk LB; Moore LW
ASAIO Trans; 1989; 35(3):308-10. PubMed ID: 2688711
[TBL] [Abstract][Full Text] [Related]
48. Self-administered daily subcutaneous recombinant human erythropoietin: an open randomised dose-finding study in ESRD patients receiving peritoneal dialysis.
Slingeneyer A; Faller B; Laroche B; Ehmer B; Mion C
Contrib Nephrol; 1991; 88():159-68. PubMed ID: 2040178
[No Abstract] [Full Text] [Related]
49. Safe employment of recombinant human erythropoietin in pregnancy in two anuric patients on regular dialysis treatment.
Rocca AR; Mazzaferro S; Stirati G; Bilancioni E; Giorlandino C
Ren Fail; 1995 Jan; 17(1):73-6. PubMed ID: 7770647
[No Abstract] [Full Text] [Related]
50. Erythropoietin and visual hallucinations in patients on dialysis.
Delanty N; Needell N
Psychosomatics; 1998; 39(1):83-5. PubMed ID: 9538683
[No Abstract] [Full Text] [Related]
51. Comment on: Recurrent skin reaction attributable to darbepoetin alfa in a patient with chronic renal failure.
Cholongitas E; Spyrou S; Georgousaki C; Dasenaki M
Ren Fail; 2010 May; 32(4):528. PubMed ID: 20446797
[No Abstract] [Full Text] [Related]
52. Side effects during recombinant human erythropoietin therapy in 2,000 ESRD patients.
Samtleben W; Ehmer B; Lutz-Knochenhauer I; Hagmann C; Scigalla P; Gurland HJ
Contrib Nephrol; 1991; 88():107-16; discussion 117. PubMed ID: 2040172
[No Abstract] [Full Text] [Related]
53. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin.
Steele RH; Limaye S; Cleland B; Chow J; Suranyi MG
Nephrology (Carlton); 2005 Jun; 10(3):317-20. PubMed ID: 15958049
[TBL] [Abstract][Full Text] [Related]
54. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem.
Singh AK
Semin Dial; 2013; 26(5):531-4. PubMed ID: 23763643
[No Abstract] [Full Text] [Related]
55. [Recombinant human erythropoietin and torasemide--innovations in nephrology].
Internist (Berl); 1989 Mar; 30(3):220. PubMed ID: 2654065
[No Abstract] [Full Text] [Related]
56. Adverse cardiovascular effects of partial correction of renal anemia by recombinant human erythropoietin.
Frei U; Nonnast-Daniel B; Schäffer J; Koch KM
Contrib Nephrol; 1990; 82():72-8. PubMed ID: 2093530
[TBL] [Abstract][Full Text] [Related]
57. Erythrocyte indices during treatment with human recombinant erythropoietin in dialysis patients.
de Jong GM; Kolsters G; Offerman JJ
Nephrol Dial Transplant; 1990; 5(1):77-8. PubMed ID: 2109289
[No Abstract] [Full Text] [Related]
58. The ESA saga: a perfect storm of failed expectations and over-regulation.
Wish J
Nephrol News Issues; 2011 Aug; 25(9):13-4. PubMed ID: 21905525
[No Abstract] [Full Text] [Related]
59. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.
Casati S; Passerini P; Campise MR; Graziani G; Cesana B; Perisic M; Ponticelli C
Br Med J (Clin Res Ed); 1987 Oct; 295(6605):1017-20. PubMed ID: 3120854
[TBL] [Abstract][Full Text] [Related]
60. Recurrent skin reaction secondary to darbepoetin alfa for two months in a patient with chronic lymphocytic leukemia.
Jabr FI; Taher A
Am J Hematol; 2007 Mar; 82(3):245. PubMed ID: 16955458
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
